COLL Collegium Pharmaceutical Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: COLL

Price (delayed)

$24.15

Market cap

$822.71M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.74

Enterprise value

$1.36B

Collegium Pharmaceutical Inc. is a specialty pharmaceutical company committed to being the leader in responsible pain management. Collegium's headquarters are located in Stoughton, Massachusetts.

Highlights
The revenue has surged by 68% year-on-year and by 28% since the previous quarter
Collegium Pharmaceutical's gross profit has increased by 39% YoY and by 32% QoQ
COLL's debt has surged by 174% year-on-year but it is down by 3.1% since the previous quarter
Collegium Pharmaceutical's EPS has plunged by 136% YoY but it has increased by 39% from the previous quarter
The equity is down by 4% year-on-year
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.collegiumpharma.com
Peers: AGRX HZNP UTHR

Key stats

What are the main financial stats of COLL
Market
Shares outstanding
34.07M
Market cap
$822.71M
Enterprise value
$1.36B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.16
Price to sales (P/S)
1.76
EV/EBIT
39.45
EV/EBITDA
7.81
EV/Sales
2.92
Earnings
Revenue
$463.93M
EBIT
$34.37M
EBITDA
$173.54M
Free cash flow
$122.61M
Per share
EPS
-$0.74
Free cash flow per share
$3.62
Book value per share
$5.8
Revenue per share
$13.71
TBVPS
$13.98
Balance sheet
Total assets
$1.17B
Total liabilities
$979.29M
Debt
$709.18M
Equity
$194.84M
Working capital
-$13.74M
Liquidity
Debt to equity
3.64
Current ratio
0.97
Quick ratio
0.83
Net debt/EBITDA
3.07
Margins
EBITDA margin
37.4%
Gross margin
45.2%
Net margin
-5.4%
Operating margin
7.2%
Efficiency
Return on assets
-2.1%
Return on equity
-12.7%
Return on invested capital
5.3%
Return on capital employed
4.6%
Return on sales
7.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

COLL stock price

How has the Collegium Pharmaceutical stock price performed over time
Intraday
1.6%
1 week
0.42%
1 month
-9.89%
1 year
24.94%
YTD
4.09%
QTD
4.09%

Financial performance

How have Collegium Pharmaceutical's revenue and profit performed over time
Revenue
$463.93M
Gross profit
$209.49M
Operating income
$33.32M
Net income
-$25M
Gross margin
45.2%
Net margin
-5.4%
The net income has plunged by 135% YoY but it has grown by 42% from the previous quarter
COLL's net margin has dropped by 121% year-on-year but it has surged by 54% since the previous quarter
Collegium Pharmaceutical's operating income has surged by 89% YoY
The revenue has surged by 68% year-on-year and by 28% since the previous quarter

Growth

What is Collegium Pharmaceutical's growth rate over time

Valuation

What is Collegium Pharmaceutical stock price valuation
P/E
N/A
P/B
4.16
P/S
1.76
EV/EBIT
39.45
EV/EBITDA
7.81
EV/Sales
2.92
Collegium Pharmaceutical's EPS has plunged by 136% YoY but it has increased by 39% from the previous quarter
The price to book (P/B) is 26% higher than the last 4 quarters average of 3.3 but 15% lower than the 5-year quarterly average of 4.9
The equity is down by 4% year-on-year
The revenue has surged by 68% year-on-year and by 28% since the previous quarter
COLL's price to sales (P/S) is 32% lower than its 5-year quarterly average of 2.6 and 7% lower than its last 4 quarters average of 1.9

Efficiency

How efficient is Collegium Pharmaceutical business performance
The ROE has shrunk by 139% YoY but it is up by 41% QoQ
The company's return on assets has shrunk by 121% YoY but it rose by 46% QoQ
The ROIC has contracted by 29% YoY
Collegium Pharmaceutical's ROS has increased by 16% YoY

Dividends

What is COLL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for COLL.

Financial health

How did Collegium Pharmaceutical financials performed over time
Collegium Pharmaceutical's total assets is 20% more than its total liabilities
Collegium Pharmaceutical's total liabilities has surged by 100% YoY but it has decreased by 2.4% QoQ
Collegium Pharmaceutical's total assets has soared by 70% YoY but it has decreased by 2.2% from the previous quarter
The debt to equity has soared by 184% YoY
COLL's debt has surged by 174% year-on-year but it is down by 3.1% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.